

Craig Thelwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9480353/publications.pdf>

Version: 2024-02-01

30
papers

678
citations

759233

12
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

927
citing authors

#	ARTICLE	IF	CITATIONS
1	An SmtB-like repressor from <i>Synechocystis</i> PCC 6803 regulates a zinc exporter. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10728-10733.	7.1	171
2	The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. <i>Blood</i> , 2011, 117, 661-668.	1.4	118
3	Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2354-2360.	3.8	70
4	The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 804-811.	3.8	51
5	Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. <i>Thrombosis Research</i> , 2018, 163, 105-116.	1.7	41
6	Differential scanning fluorimetry: Rapid screening of formulations that promote the stability of reference preparations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 77, 163-166.	2.8	33
7	Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. <i>FEBS Letters</i> , 2005, 579, 3303-3309.	2.8	30
8	Fibrin Binding and the Regulation of Plasminogen Activators during Thrombolytic Therapy. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008, 6, 212-223.	1.0	30
9	Mechanism of plasmin generation by S100A10. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1058-1071.	3.4	21
10	Inhibition of Catalytic and Glucan-Binding Activities of a Streptococcal GTF Forming Insoluble Glucans. <i>Caries Research</i> , 2002, 36, 353-359.	2.0	15
11	The poor quality of streptokinase products in use in developing countries. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1092-1093.	3.8	14
12	Activity Regulation by Fibrinogen and Fibrin of Streptokinase from <i>Streptococcus Pyogenes</i> . <i>PLoS ONE</i> , 2017, 12, e0170936.	2.5	13
13	Fractal Kinetic Behavior of Plasmin on the Surface of Fibrin Meshwork. <i>Biochemistry</i> , 2014, 53, 6348-6356.	2.5	11
14	An international collaborative study to establish the WHO 1st international standards for Clâ€inhibitor, plasma and concentrate. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2097-2099.	3.8	9
15	Biosimilars: the process is the product. The example of recombinant streptokinase. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1229-1233.	3.8	9
16	An international collaborative study to investigate a proposed reference method for the determination of potency measurements of fibrinolytics in absolute units. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 412-414.	3.8	7
17	Biological Standards for Potency Assignment to Fibrinolytic Agents Used in Thrombolytic Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 205-213.	2.7	7
18	Fibrinolysis standards: A review of the current status. <i>Biologicals</i> , 2010, 38, 437-448.	1.4	6

#	ARTICLE	IF	CITATIONS
19	An international collaborative study to establish the WHO 1st international standard for alpha-1-antitrypsin. <i>Vox Sanguinis</i> , 2011, 101, 83-89.	1.5	5
20	Structure, Mechanical, and Lytic Stability of Fibrin and Plasma Coagulum Generated by Staphylocoagulase From <i>Staphylococcus aureus</i> . <i>Frontiers in Immunology</i> , 2019, 10, 2967.	4.8	5
21	An international collaborative study to calibrate the WHO 2nd International Standard for Ancrod (15/106) and the WHO Reference Reagent for Batroxobin (15/140): communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1003-1006.	3.8	4
22	Regulatory frameworks in developing countries. <i>Nature Biotechnology</i> , 2005, 23, 413-413.	17.5	3
23	An International Collaborative Study to establish the WHO 2nd International Standard for High Molecular Weight Urokinase: communication from SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 415-417.	3.8	2
24	An International Collaborative Study to establish the World Health Organization 4th International Standard for Plasmin (13/206): communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 215-218.	3.8	1
25	A new WHO reference reagent for activated blood coagulation factor X (FXa), human (15/102). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 255-257.	3.8	1
26	Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry. <i>Analytical Biochemistry</i> , 2022, 638, 114413.	2.4	1
27	An international collaborative study to establish the World Health Organization 2nd International Standard for Factor VII Concentrate: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1750-1753.	3.8	0
28	Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 695-697.	3.8	0
29	Investigating the functional relationship between streptokinase variants from Group A <i>Streptococcus</i> , and associated M-like proteins. <i>Access Microbiology</i> , 2020, 2, .	0.5	0
30	Investigating the impact of M1 protein from Group A <i>Streptococcus</i> on fibrin clot formation, structure and fibrinolytic potential. <i>Access Microbiology</i> , 2020, 2, .	0.5	0